Cann Group has been granted a GMP licence by the Therapeutic Goods Administration (TGA) for its Southern facility in Melbourne.
It has also been inspected by the regulator for another GMP licence at its Mildura, Victoria site.
The licence enables Cann to manufacture active pharmaceutical ingredient (API) and medicinal cannabis products under GMP conditions at the Southern facility for supply in Australia and overseas.
The move follows a significant upgrade to the site largely funded by a capital raise in July and August last year.
Dried cannabis flower products produced under the licence are expected to be available to patients under the special access and authorised prescriber schemes in the next few weeks.
CEO Peter Crock described the move as an important achievement for Cann as it develops its integrated supply chain.
He added: “Over the last 12 months, we have seen increasing demand for GMP products from both domestic and international customers and have had pre-orders in place since late last year. We are now able to service the needs of those customers.”
Meanwhile, Cann’s Mildura facility was recently inspected by the TGA in respect of a GMP licence application to manufacture therapeutic goods and undertake GMP testing.
The firm said once granted, the Mildura licence will enable it to manufacture cannabis extract (API) and Satipharm CBD capsules. It will also allow Cann to operate a GMP-certified chemical, physical and microbiological laboratory for analytical testing of dried flower and various medicinal cannabis products and excipients.
Cann told the ASX the capability will be critical in enabling it to “demonstrate that products meet local and overseas regulatory requirements”.
